Clinical trial · Interventional
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
Endoscopic Ultrasound-guided Fine-needle Injection for Multiple Endocrine Neoplasia Type 1-related Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study
NCT05554744CI-TRIAL-00061051unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study aims to evaluate the feasibility, safety and efficacy of EUS-FNI for MEN1-related pNETs
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Endocrine Neoplasia Type 1 | Multiple Endocrine Neoplasia Type 1 | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS-guided fine-needle injection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MEN1-1-related pNETs
- description
- The patients with MEN1-1-related pNETs will undergo EUS-FNI with ethanol or lauromacrogol
- interventionNames
- Procedure: EUS-guided fine-needle injection
Primary outcomes (4)
- measure
- Changes of blood glucose level
- timeFrame
- Within 7 days of the last ablation and every 6 months up to 24 months
- description
- Changes in the lowest blood glucose levels between baseline and last treatment and each study visit
- measure
- Changes of insulin level
- timeFrame
- Within 7 days of the last ablation and every 6 months up to 24 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with MEN1-1-related pNETs are evaluated by histopathology and genetic testing. 2. Patients who refuse surgery. 3. Patients who have given their fully informed consent. Exclusion Criteria: 1. Patients who are not suitable for the endoscopic procedure. 2. Patients who have blood coagulation dysfunction, mental disorders, mild or severe cardiorespiratory.
References
Publications (0)
Data not yet available
No reference posted for this study.